(Press-News.org) SEATTLE, WASH. — October 9, 2025 — In an exciting scientific first, researchers at the Allen Institute successfully designed a new gene therapy that reversed symptoms related to SYNGAP1-related disorders (SRD) in mice. These are a class of brain disorders that can lead to severe and debilitating symptoms including intellectual disability, epilepsy, motor problems, and risk-taking behaviors in humans. In most cases, SRDs are caused when someone has only one working copy of the SYNGAP1 gene instead of the normal two.
The findings, recently published in the journal Molecular Therapy, represent the first successful gene supplementation therapy for SRDs in which an adeno associate virus (AAV) was used to deliver a working copy of the SYNGAP1 gene into brain cells. AAVs are non-replicating viruses that act like delivery trucks carrying therapeutic cargo, in this case the SYNGAP1 gene, into cells that need it.
“Gene supplementation is providing a functional new copy of a defective gene, a strategy that has great potential for correcting diseases where a gene is completely missing or where a single copy of a gene is lost,” said Boaz Levi, Ph.D., associate investigator at the Allen Institute and senior author of the study. “This provides a clear demonstration that SYNGAP1-related disorders can be treated with a neuron-specific gene supplementation strategy. It’s an important milestone for the field that provides hope for those who suffer from this class of severe neurological diseases.”
What Were the Most Important Findings?
The new gene therapy improved a broad range of disease symptoms, nearly eliminating epileptic brain activity and correcting hyperactive behavior and risk-taking tendencies characterized by SRDs. The treatment also substantially restored normal brain wave patterns, which is significant because abnormal brain rhythms in SRD patients are tied to cognitive dysfunction affecting learning, memory, and attention.
Notably, the study also revealed something important about the timing of when this therapy was given: Researchers treated juvenile mice, an age corresponding to when children are usually diagnosed. At this stage, the mice’s symptoms dramatically improved, suggesting that this gene therapy could still be effective even after symptoms begin. This encouraging finding offers hope that treatment may help restore normal brain function in children with SRDs.
What Are the Practical Implications?
This discovery is an encouraging development for families affected by SRDs. Right now, there are few treatment options and drugs available for families to find relief, and those that are available are limited to managing severe symptoms without addressing the root cause. This new research, if successful in human trials, could lead to new therapies that alleviate symptoms by targeting the genetic origins of disease rather than addressing symptoms alone.
How Did Researchers Do It?
Scientists faced a technical barrier in designing the new therapy. The defective copy of the SYNGAP1 gene needs to be replaced, but this gene is too large to fit into AAV delivery systems. In this case, researchers built the oversized gene and packaged it into the AAV, much like loading a truck filled with more luggage than anyone thought it could hold. Surprisingly, it all fit, and the therapy was successfully delivered into targeted brain cells.
While clinical trials are still needed, the strong evidence and data in this study suggest that effective treatment for SRDs and their devastating symptoms may be within reach. The range of therapeutic benefits was also significant—addressing seizures, behavior, and brain function simultaneously.
This hopeful development for science represents the kind of transformative potential that patients and families desperately need for this debilitating class of brain diseases.
About the Allen Institute
The Allen Institute is an independent, 501(c)(3) nonprofit research organization founded by philanthropist and visionary, the late Paul G. Allen. The Allen Institute is dedicated to answering some of the biggest questions in bioscience and accelerating research worldwide. The Institute is a recognized leader in large-scale research with a commitment to an open science model. Its research institutes and programs include the Allen Institute for Brain Science, the Allen Institute for Cell Science, the Allen Institute for Immunology, and the Allen Institute for Neural Dynamics. In 2016, the Allen Institute expanded its reach with the launch of the Paul G. Allen frontiers group, which identifies pioneers with new ideas to expand the boundaries of knowledge and make the world better. For more information, visit alleninstitute.org.
# # #
Media Contact
Liz Dueweke
Sr. Communication and Media Relations Specialist
liz.dueweke@alleninstitute.org
206-519-8527
END
New research has discovered that briefly altering how we perceive our own body can help unlock autobiographical memories – potentially even those from the early stages of childhood.
Published in the Nature journal Scientific Reports, the study is the first to find that adults can better access their early memories after embodying a childlike version of their own face.
Led by neuroscientists at Anglia Ruskin University (ARU) in Cambridge, the study of 50 adult participants involved an “enfacement illusion”, which allows people to experience a face they see on a computer screen as their own, as though looking in a mirror.
The participants ...
A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help reverse changes in the immune system caused by menopause, potentially booting immune health. The research reveals new evidence that menopause significantly alters women’s immune system, increasing their vulnerability to infections.
The study, published in Aging Cell is the first detailed analysis of how ageing and sex differences influence monocytes, a key group of immune cells that act as the body’s first responders to infection. Analysing blood samples from younger adults less than 40 years of age and older ...
Melting ice sheets in North America played a far greater role in driving global sea-level rise at the end of the last ice age than scientists had thought, according to a Tulane University-led study published in Nature Geoscience.
The findings overturn decades of conventional wisdom about how Earth emerged from its last great freeze and could reshape how scientists view the risks of climate change in today’s warming world.
Between 8,000 and 9,000 years ago, retreating North American ice sheets alone caused more than 30 feet (about 10 meters) of global sea-level rise. For years, scientists ...
Embargoed until publication in Nature Chemical Biology on Oct. 9, 2025 at 10:00am (London time) / 05:00am (US Eastern Time).
Targeted drug delivery is a powerful and promising area of medicine. Therapies that pinpoint the exact areas of the body where they’re needed — and nowhere they’re not — can reduce the medicine dosage and avoid potentially harmful “off target” effects elsewhere in the body. A targeted immunotherapy, for example, might seek out cancerous tissues and activate immune cells to fight the disease only in those tissues.
The tricky part ...
The fossil fuel industry is falling far short of its pledge to lead the energy transition, according to new research from the Institute of Environmental Science and Technology at the Universitat Autònoma de Barcelona (ICTA-UAB). The study shows that the world’s largest oil and gas companies are responsible for only 1.42% of renewable energy projects worldwide.
The research, recently published in Nature Sustainability, challenges the dominant narrative promoted by the fossil fuel industry that positions itself as a key player in tackling climate ...
PULLMAN, Wash. — Planting wheat earlier in the spring to avoid crop damage from ever-hotter summers may not keep harvests on pace with current levels.
That’s a key finding from new research at Washington State University challenging assumptions that earlier planting could offset the effects of a warming climate. Researchers used computer modeling to show that moving crop plantings earlier in the season brings about other plant growth issues that could hinder productivity.
The findings were published in Communications, Earth, and Environment.
“Over the years, a lot of studies addressing climate change in agriculture have talked in positive terms about ...
Researchers at Umeå University have identified a key molecular player that helps bacteria survive the hostile environment inside the body. Their study reveals how the protein RfaH acts as a protective shield for bacterial genes — and points to new strategies for fighting persistent infections.
“The human body is a very stressful place for bacteria,” says Kemal Avican, research group leader at Department of Molecular Biology and Icelab at Umeå University and leader of the study. “During infection, the immune system attacks, nutrients are scarce, and microbes are exposed to bile salts, acids and heat. We looked at how RfaH helps bacteria deal with ...
Tokyo, Japan – [Sept 18, 2025] –
A team of researchers from Keio University School of Medicine, the Institute of Medical Science at the University of Tokyo, and the National Center for Child Health and Development has reported the first cross-disease, cross-stakeholder survey on PPIE in Japan. The study compared allergy research with cancer and rare diseases, fields where PPIE has already advanced.
The survey revealed that:
•100% of allergy-related PAGs considered PPIE essential, and 50% had formal rules for engagement.
•By contrast, only 9.4% of allergy researchers reported established rules, and just ...
Amsterdam, October 9, 2025 – An important new study in the Journal of Hepatology, published by Elsevier, reports the world’s first auxiliary liver xenotransplant from a genetically engineered pig to a living human recipient. The patient survived for 171 days, offering proof-of-concept that genetically modified porcine livers can support key metabolic and synthetic functions in humans, while also underscoring the complications that currently limit long-term outcomes.
According to the World Health Organization, thousands of patients die every year while waiting for organ transplants due to the limited supply ...
Between Jan 2024 and Aug 2025, peaks in the prevalence of acute malnutrition match periods of severe aid restrictions.
More than 54,600 children in Gaza are estimated to be acutely malnourished, including over 12,800 severely so, with few therapeutic options available to them. With measurements up to the middle of August 2025, the study comprehensively tracks wasting among children during the war, estimates population prevalence, and highlights unprecedented increases in child malnutrition following periods of blockades and severe ...
